Co-expression of CD31 and nucleolin (CD31^high/NCL^high) predicts significantly worse disease-free survival in early-stage NSCLC [29], and dual immunostaining of CD31 with α-SMA can stratify vascular maturity and patient risk [30]. The gene discussed is NUCLEOLIN; the disease is non-small cell lung carcinoma.